BackgroundDevelopment of new treatments for Alzheimer's disease (AD) has broadened into early interventions in individuals with modest cognitive impairment and a slow decline. The 11-item version of the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) was originally developed to measure cognition in patients with mild to moderate AD. Attempts to improve its properties for early AD by removing items prone to ceiling and/or by adding cognitive measures known to be impaired early have yielded a number of ADAS-Cog variants. Using Alzheimer's Disease Neuroimaging Initiative data, we compared the performance of the 3-, 5-, 11- and 13-item ADAS-Cog variants in subjects with early AD. Given the interest in enrichment strategies, w...
Mild cognitive impairment (MCI) has emerged as a classification for a prodromal phase of cognitive d...
Background: Amnestic Mild cognitive impairment (aMCI) is considered to be the transitional stage bet...
INTRODUCTION: Early identification of Alzheimer's disease (AD) is needed both for clinical trials an...
Background Development of new treatments for Alzheimer’s disease (AD) has broadened into early inter...
The aim of this study was to verify the usefulness of Alzheimer Disease Assessment Scale-cognitive s...
Background: The Alzheimer’s Disease Assessment Scale cognitive subscale (ADAS-Cog) is widely used in...
Recent clinical trials in mild Alzheimer disease (AD) have enriched for amyloid-specific positron em...
Objectives Preclinical Alzheimers disease (AD) patients may or may not show cognitive impairment on ...
Several neuropsychological tests and biomarkers of Alzheimer's disease (AD) have been validated and ...
<div><p>The tau and amyloid pathobiological processes underlying Alzheimer disease (AD) progresses s...
The tau and amyloid pathobiological processes underlying Alzheimer disease (AD) progresses slowly ov...
This study modeled predementia Alzheimer's disease clinical trials. Longitudinal data from cognitive...
Background: There are discrepant findings regarding which subscales of the Cambridge Cognitive Exami...
The cognitive subscale of the "Alzheimer's Disease Assessment Scale" (ADAS-Cog) is widely used for t...
Objective: This study measured the annual rate ofcognitive change in patients with Alzhei-mer’s dise...
Mild cognitive impairment (MCI) has emerged as a classification for a prodromal phase of cognitive d...
Background: Amnestic Mild cognitive impairment (aMCI) is considered to be the transitional stage bet...
INTRODUCTION: Early identification of Alzheimer's disease (AD) is needed both for clinical trials an...
Background Development of new treatments for Alzheimer’s disease (AD) has broadened into early inter...
The aim of this study was to verify the usefulness of Alzheimer Disease Assessment Scale-cognitive s...
Background: The Alzheimer’s Disease Assessment Scale cognitive subscale (ADAS-Cog) is widely used in...
Recent clinical trials in mild Alzheimer disease (AD) have enriched for amyloid-specific positron em...
Objectives Preclinical Alzheimers disease (AD) patients may or may not show cognitive impairment on ...
Several neuropsychological tests and biomarkers of Alzheimer's disease (AD) have been validated and ...
<div><p>The tau and amyloid pathobiological processes underlying Alzheimer disease (AD) progresses s...
The tau and amyloid pathobiological processes underlying Alzheimer disease (AD) progresses slowly ov...
This study modeled predementia Alzheimer's disease clinical trials. Longitudinal data from cognitive...
Background: There are discrepant findings regarding which subscales of the Cambridge Cognitive Exami...
The cognitive subscale of the "Alzheimer's Disease Assessment Scale" (ADAS-Cog) is widely used for t...
Objective: This study measured the annual rate ofcognitive change in patients with Alzhei-mer’s dise...
Mild cognitive impairment (MCI) has emerged as a classification for a prodromal phase of cognitive d...
Background: Amnestic Mild cognitive impairment (aMCI) is considered to be the transitional stage bet...
INTRODUCTION: Early identification of Alzheimer's disease (AD) is needed both for clinical trials an...